Week | BL | Tx | W24 | W25 | W26 | W27 | W28 | W30 | W34 | W38 | W42 | W46 | W52 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Informed consent | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Medical history | X | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Transplantation information | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Concomitant medication | X | X | X | X | X | X | X | X | X | X | X | X | X |
Physical examination | X | X | X | X | X | X | X | X | X | X | X | X | X |
Routine lab | X | X | X | X | X | X | X | X | X | X | X | X | X |
Urinalysis | X | X | X | X | X | X | X | X | X | X | X | X | X |
CMV, EBV and BK viral load | Â | Â | X | X | Â | X | Â | X | Â | X | Â | X | X |
MSC infusion | Â | Â | Â | X | X | Â | Â | Â | Â | Â | Â | Â | Â |
Renal biopsy | Â | X | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
Iohexol clearance | Â | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
Immune monitoring | Â | X | X | Xa | Xa | X | Â | Â | X | Â | Â | Â | X |
DSA | X | X | X | Â | Â | Â | Â | X | Â | Â | Â | Â | X |
Safety assesment | X | X | X | X | X | X | X | X | X | X | X | X | X |